10 Year Financial Data of Nektar Therapeutics, Inc. (NKTR)

9.24 (1y: +33%)

Market Cap	1.12 B	P/E(ttm)
Enterprise Value	1.02 B	P/B	22.80

NKTR- NAS (USA)
Nektar Therapeutics, Inc.

Currently 1/5

Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$9.24

2 Severe Warning Signs 1 Medium Warning Sign 1 Good Sign

Bookmark

Annual Rates (per share)	10 yrs*	5 yrs*	12 months*
Revenue Growth (%)	-10.6	-8.2	8.7
EBITDA Growth (%)	-5.1	12.2	0
Free Cash Flow Growth (%)	0	0	0
Book Value Growth (%)	-19.5	-19.5	-101.4

*12-month growth rate is calculated with the per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 5-year and 10-year numbers.

Trendline:

Export:

Print This Table Print

See this page for the explanation of the data and charts * All numbers are in millions except for per share data

Per Share Data	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue per Share ($)	1.90	1.46	1.47	2.42	2.97	0.98	0.78	1.69	0.63	0.71	0.75	0.16	0.21	0.16	0.18	0.20
EBITDA per Share	-0.86	-0.70	-1.82	-1.41	-0.09	-0.65	-0.87	-0.12	-0.96	-1.10	-1.16	-0.30	-0.21	-0.25	-0.34	-0.36
Free Cashflow per Share	-1.70	-1.34	-1.12	-1.28	1.24	-1.78	0.21	-0.93	-1.09	-1.22	-1.23	-0.32	-0.19	-0.26	-0.45	-0.33
Earnings per Share ($)	-0.84	-1.30	-2.15	-1.72	-0.36	-0.37	-1.11	-0.40	-1.19	-1.50	-1.62	-0.36	-0.30	-0.38	-0.46	-0.48
Book Value per Share	2.94	5.96	3.80	2.53	2.33	2.06	1.10	0.96	1.75	0.41	-0.02	1.42	1.15	0.83	0.41	-0.02
Month End Stock Price	13.61	20.24	16.46	15.21	6.71	5.56	9.32	12.85	5.60	7.41	11.00	7.92	8.07	10.68	7.41	11.00
Ratios	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Return on Equity %	-28.40	-21.80	-56.60	-68.20	-15.30	-18.10	-100	-41.80	-67.70	-366	--	-101	-104	-183	-450	--
Return on Assets %	-7.60	-13.70	-21.60	-20.10	-4.50	-6.10	-17.80	-7.30	-22.10	-34.50	-49.20	-23.60	-20.40	-32.00	-42.40	-49.20
Return on Capital - Joel Greenblatt %	-53.10	-55.60	-157	-107	-60.70	-255	--	-44.30	-232	-454	-1,024	-260	-228	-418	-558	-1,024
Debt to Equity	2.40	0.43	1.34	1.93	1.58	1.24	2.28	2.56	1.16	2.91	-51.82	1.41	1.73	1.44	2.91	-51.82

Gross Margin %	86.20	82.70	71.50	45.80	46.00	61.10	57.00	83.90	69.40	62.50	49.30	51.50	69.60	60.70	65.50	49.30
Operating Margin %	-62.30	-64.70	-145	-73.10	-13.20	-91.60	-132	-17.80	-173	-174	-197	-211	-114	-179	-205	-197
Net Margin %	-43.90	-89.20	-147	-71.10	-12.00	-38.10	-143	-23.90	-187	-212	-239	-229	-145	-237	-250	-239

Days Sales Outstanding	21.10	41.00	23.70	79.00	28.90	45.20	24.40	57.60	25.20	26.10	14.40	54.80	43.70	19.30	25.00	14.40
Days Inventory	213	197	189	45.30	30.20	97.10	76.30	103	211	219	143	147	186	211	228	143
Inventory Turnover	1.70	1.90	1.90	8.10	12.10	3.80	4.80	3.50	1.70	1.70	0.60	0.60	0.50	0.40	0.40	0.60

Debt to Revenue	3.70	1.74	3.47	2.01	1.24	2.61	3.25	1.46	3.21	1.68	5.90	12.75	9.63	7.46	6.46	5.90
COGS to Revenue	0.14	0.17	0.29	0.54	0.54	0.39	0.43	0.16	0.31	0.37	0.51	0.49	0.30	0.39	0.34	0.51
Inventory to Revenue	0.08	0.09	0.15	0.07	0.05	0.10	0.09	0.05	0.18	0.23	0.80	0.79	0.62	0.91	0.86	0.80
Interest Exp. to Revenue %	-11.80	-16.75	-0.84	1.47	1.31	-2.99	-11.80	-6.05	-11.16	-38.47	-42.92	-20.62	-30.83	-57.47	-45.63	-42.92

Asset Turnover	0.17	0.15	0.15	0.28	0.38	0.16	0.13	0.31	0.12	0.16	0.05	0.03	0.04	0.03	0.04	0.05
Buyback Ratio	5.50	207	22.90	14.40	11.50	1.10	4.70	23.40	167	2.40	2.20	1.20	2.50	4.20	1.80	2.20
Income Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue	106	114	126	218	273	90.19	71.93	159	71.48	81.19	86.25	17.95	23.68	18.41	21.15	23.00
Cost of Goods Sold	14.68	19.80	36.00	118	148	35.04	30.95	25.67	21.89	30.43	33.38	8.71	7.20	7.23	7.29	11.66
Gross Profit	91.58	94.47	90.28	99.63	126	55.15	40.98	133	49.59	50.76	52.86	9.24	16.48	11.18	13.86	11.34

Selling, General, &Admin. Expense	22.02	30.97	43.85	78.32	56.34	51.50	41.01	40.99	46.76	41.61	42.33	10.41	10.27	10.07	10.86	11.13
Research &Development	132	134	152	149	154	154	95.11	108	127	149	159	35.09	33.20	34.02	46.37	45.62
Earnings Before DDA	-47.77	-54.76	-156	-127	-7.99	-60.16	-80.25	-11.70	-109	-127	-134	-34.45	-23.52	-29.26	-39.47	-41.78

Depreciation, Depletion and Amortization	18.42	19.19	26.23	32.64	28.15	22.49	14.88	16.55	14.95	14.51	14.66	3.48	3.47	3.64	3.91	3.63

Operating Income	-66.19	-73.94	-183	-159	-36.15	-82.65	-95.13	-28.26	-124	-141	-149	-37.93	-26.99	-32.90	-43.38	-45.40
Interest Income/Expense	-12.54	-19.15	-1.06	3.19	3.56	-2.70	-8.49	-9.63	-7.98	-31.23	-37.40	-3.70	-7.30	-10.58	-9.65	-9.87
Net Income	-46.68	-102	-185	-155	-32.76	-34.34	-103	-37.94	-134	-172	-186	-41.10	-34.29	-43.55	-52.93	-55.06

Earnings per Share ($)	-0.84	-1.30	-2.15	-1.72	-0.36	-0.37	-1.11	-0.40	-1.19	-1.50	-1.62	-0.36	-0.30	-0.38	-0.46	-0.48
Total Shares Outstanding	55.82	78.46	85.92	89.79	91.88	92.41	92.77	94.08	113	115	115	115	115	115	115	115
Balance Sheet	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Cash and cash equivalents	286	419	476	459	482	379	396	316	241	277	236	382	433	319	277	236
Accounts Receivable	6.15	12.84	8.21	47.15	21.64	11.16	4.80	25.10	4.94	5.81	3.65	10.80	11.36	3.91	5.81	3.65
Inventory	8.56	10.69	18.63	14.66	12.19	9.32	6.47	7.27	12.66	18.27	18.38	14.11	14.72	16.75	18.27	18.38
Other Current Assets	5.82	12.27	16.81	14.60	7.11	6.75	6.18	5.68	17.94	13.36	8.81	13.63	9.34	7.00	13.36	8.81
Total Current Assets	306	455	520	535	523	406	414	354	277	315	267	421	468	347	315	267

Property, Plant and Equipment	149	151	142	134	114	73.58	78.26	89.77	78.58	72.22	70.11	75.56	73.71	73.26	72.22	70.11
Intangible Assets	141	137	91.88	82.06	81.11	76.50	76.50	76.50	76.50	76.50	76.50	76.50	76.50	76.50	76.50	76.50
Other Long Term Assets	19.82	2.56	105	17.27	6.29	4.24	7.09	0.97	175	34.44	34.25	122	49.94	44.75	34.44	34.25
Total Assets	617	745	859	768	725	561	576	521	607	498	448	695	668	541	498	448

Accounts Payable	24.07	22.21	39.88	38.14	71.16	52.95	31.64	37.13	34.45	44.23	47.32	30.43	33.88	34.96	44.23	47.32
Current Portion of Long-Term Debt	1.63	1.55	0.48	103	2.34	--	--	--	215	--	--	215	215	--	--	--
Other Current Liabilities	21.16	31.90	29.23	23.81	24.60	15.43	121	26.98	26.13	34.31	35.91	25.37	28.03	34.51	34.31	35.91
Total Current Liabilities	46.86	55.65	69.60	165	98.09	68.37	153	64.11	276	78.54	83.22	271	277	69.47	78.54	83.22

Long-Term Debt	392	198	438	335	337	235	234	232	14.58	137	136	13.89	13.17	137	137	136
Other Long-Term Liabilities	14.07	24.41	24.22	41.04	75.94	66.71	86.38	134	119	236	232	248	246	239	236	232
Total Liabilities	453	278	532	541	511	370	473	431	409	451	451	532	536	446	451	451

Common Stock	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Retained Earnings	-596	-717	-902	-1,057	-1,090	-1,124	-1,227	-1,265	-1,399	-1,570	-1,625	-1,440	-1,474	-1,517	-1,570	-1,625
Additional Paid-In Capital	759	1,188	1,234	1,284	1,303	1,313	1,328	1,354	1,597	1,618	1,623	1,602	1,607	1,613	1,618	1,623
Total Equity	164	467	327	227	214	190	102	90.66	198	47.02	-2.62	162	132	95.33	47.02	-2.62
Cashflow Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Net Income	-46.68	-102	-185	-155	-32.76	-34.34	-103	-37.94	-134	-172	-186	-41.10	-34.29	-43.55	-52.93	-55.06
Depreciation, Depletion and Amortization	18.42	19.19	26.23	32.64	28.15	22.49	14.88	16.55	14.95	14.51	14.66	3.48	3.47	3.64	3.91	3.63
Cash Flow from Others	-47.94	4.56	80.88	29.41	151	-134	127	-34.48	5.29	27.59	37.92	3.00	10.22	12.73	1.64	13.32
Cash Flow from Operations	-76.20	-78.14	-78.00	-92.72	146	-146	39.74	-55.87	-114	-130	-133	-34.62	-20.59	-27.17	-47.38	-38.11

Investment for Property, Plant & Equipement	-18.75	-27.19	-17.96	-22.52	-32.80	-18.86	-20.70	-31.46	-9.72	-10.58	-9.38	-1.52	-1.66	-2.57	-4.84	-0.32
Cash Flow from Acquisitions	--	--	-30.71	--	--	--	--	--	--	--	--	--	--	--	--	--
Cash Flow from Investing	4.07	-88.91	32.40	-117	-32.66	275	-149	16.71	-112	113	108	48.43	7.76	-5.39	62.23	43.69

Net Issuance of Stock	2.55	211	42.42	22.26	3.78	0.38	4.82	8.89	224	4.12	4.86	0.48	0.86	1.84	0.94	1.22
Net Issuance of Debt	98.75	-3.95	232	-10.49	-106	-50.13	-1.29	-1.36	-1.98	-96.90	-97.03	-0.57	-0.59	-95.02	-0.73	-0.69
Other Financing	0.00	--	-0.00	--	0.00	0.00	--	--	0.00	120	-3.00	120	--	-0.00	--	-3.00
Cash Flow from Financing	101	207	275	11.77	-102	-49.74	3.54	7.54	222	26.80	-95.18	120	0.27	-93.18	0.21	-2.47

Net Change in Cash	29.17	40.36	229	-198	12.53	79.29	-106	-31.84	-2.44	10.13	-120	133	-12.33	-126	15.10	3.09

Free Cash Flow	-94.95	-105	-95.95	-115	114	-165	19.04	-87.33	-123	-140	-143	-36.13	-22.25	-29.74	-52.22	-38.43
Valuation Ratios (Daily)	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Price to Tangible Book
Price-to-Free-Cash-Flow ratio
PS Ratio
EV-to-Revenue
Forward Rate of Return
Shiller PE Ratio
Valuation and Quality	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Market Cap
Enterprise Value
Month End Stock Price
Net Cash (per share)
Net Current Asset Value (per share)
DCF (per share)
Median PS (per share)
Peter Lynch Fair Value (per share)
Altman Z-Score
Piotroski F-Score
Beneish M-Score

Switch to Another Stock:

NKTR Quarterly/Annuals Reports

NKTR: 10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer): (10-Q) - 2012-08-09
NKTR: 10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer): (10-Q) - 2012-05-03
NKTR: 10-K - NEKTAR THERAPEUTICS (0000906709) (Filer): (10-K) - 2012-02-29
NKTR: 10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer): (10-Q) - 2011-08-05
NKTR: 10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer): (10-Q) - 2011-04-29

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

NKTR Quarterly/Annuals Reports